Chi­na’s cheap, fast and qui­et sys­tem for test­ing cut­ting-edge med­i­cines is fac­ing scruti­ny af­ter the deaths of three peo­ple in in­ves­ti­ga­tor-ini­ti­at­ed tri­als.

The stud­ies...

More than four months in­to PhRMA’s search for a new CEO, the lob­by­ing group has con­sid­ered Re­pub­li­can can­di­dates with ex­pe­ri­ence span­ning decades on Capi­tol Hill...

The FDA late last month re­ject­ed Os­teal Ther­a­peu­tic­s' lead com­bo ther­a­py that sought to more quick­ly fight the bac­te­ria or oth­er mi­croor­gan­isms that in­fect the...

Eli Lil­ly’s triple ag­o­nist re­ta­tru­tide ap­pears to be the most ef­fec­tive obe­si­ty drug to have reached late-stage tri­als, with weight loss of up to 25%...

Ul­tragenyx has se­cured its first ap­proved gene ther­a­py, with the FDA clear­ing its as­set for an ul­tra-rare dis­ease that can cause life-threat­en­ing blood sug­ar crash­es...

The FDA has been qui­et­ly se­lect­ing par­tic­i­pants for its TEM­PO pi­lot. A third, the be­hav­ioral health com­pa­ny Lim­bic, was just added to the pi­lot’s web­page, fol­low­ing re­mote...